CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 25 enrolled
Drug / intervention
CyPath®device
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02388074
NCT02388074N/ACompleted
CompareCT.gov

Sputum Labeling Utilizing Synthetic Meso Tetra (4-Carboxyphenyl) Porphine (TCPP) for Detection of Lung Cancer

bioAffinity Technologies Inc.·interventional·Posted Mar 13, 2015·Updated Jul 14, 2015

In Brief

A clinical study evaluating CyPath® for Lung Cancer. Completed, enrolled 25 participants across 1 site.

Detailed Summary

This is a single center study to assess the efficacy of CyPath® Early Detection Lung Cancer Assay to detect lung cancer cells from deep lung sputum.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLung Cancer
CountriesUnited States
CollaboratorsRadiology Associates of Albuquerque

Timeline

N/ACompletedFinished
201520162017201820192020202120222023202420252026
First PostedMar 13, 2015
Enrollment StartMar 1, 2015
Primary CompletionApr 1, 2015
TodayJul 2, 2026
Enrollment to primary: 1 monthPosted 11.3 years ago

Interventions

CyPath®device

CyPath® diagnostic assay for the early detection of lung cancer using sputum